Anika Therapeutics - ANIK Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIK shares.
View ANIK analyst ratings or view top-rated stocks.

2 brokerages have issued twelve-month price objectives for Anika Therapeutics' stock. Their ANIK share price forecasts range from $26.00 to $31.00. On average, they anticipate the company's stock price to reach $28.50 in the next twelve months. This suggests that the stock has a possible downside of 8.7%.
View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts.

Anika Therapeutics' stock was trading at $29.60 at the start of the year. Since then, ANIK shares have increased by 5.4% and is now trading at $31.21.
View the best growth stocks for 2023 here.

Anika Therapeutics saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 542,800 shares, a decrease of 17.3% from the December 31st total of 656,200 shares. Based on an average daily trading volume, of 101,400 shares, the days-to-cover ratio is presently 5.4 days. Approximately 3.8% of the shares of the stock are short sold.
View Anika Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our ANIK earnings forecast.

Anika Therapeutics, Inc. (NASDAQ:ANIK) announced its quarterly earnings results on Tuesday, November, 8th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.13. The biotechnology company had revenue of $40.26 million for the quarter, compared to analysts' expectations of $36.56 million. Anika Therapeutics had a negative net margin of 10.33% and a negative trailing twelve-month return on equity of 2.49%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Anika Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.91%), Allspring Global Investments Holdings LLC (0.33%), Assenagon Asset Management S.A. (0.33%), Ziegler Capital Management LLC (0.13%), Los Angeles Capital Management LLC (0.07%) and Riverwater Partners LLC (0.07%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, James Loerop, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land.
View institutional ownership trends.

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANIK stock can currently be purchased for approximately $31.21.

Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $455.98 million and generates $147.79 million in revenue each year. The biotechnology company earns $4.13 million in net income (profit) each year or ($1.09) on an earnings per share basis.

The company employs 297 workers across the globe.

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720.